Summary & Overview
HCPCS J2300: Nalbuphine Hydrochloride Injection, per 10 mg
HCPCS Level II code J2300 designates the injection of nalbuphine hydrochloride billed per 10 mg. Nalbuphine is an opioid agonist-antagonist used for acute moderate to severe pain and as an adjunct in perioperative and emergency care. The code matters nationally because it standardizes reporting for an injectable analgesic that may be used across multiple acute care settings, supporting consistent billing, utilization tracking, and formulary management.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and common billing considerations. The publication outlines benchmarking elements such as typical use cases and payer coverage patterns where available, policy and reimbursement updates affecting HCPCS coding for injectable analgesics, and operational notes for claims processing.
This summary provides information to help revenue cycle, clinical pharmacy, and compliance teams understand how J2300 is used in practice, how it fits into acute care medication administration workflows, and what to expect from major payers and Medicare regarding coverage and coding practice. Data not available in the input for specific payers’ coverage policies and utilization rates is noted where applicable.
Billing Code Overview
HCPCS Level II code J2300 represents an injectable formulation of nalbuphine hydrochloride, billed per 10 mg. This code is used for administration of nalbuphine, an opioid agonist-antagonist analgesic that is commonly employed for moderate to severe pain management in acute care settings.
Service Type: Injectable analgesic medication administration
Typical Site of Service: Hospital inpatient, emergency department, ambulatory surgical centers, and other acute care settings
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult presenting to an outpatient infusion center, emergency department, or ambulatory surgical center with moderate to severe acute pain where opioid agonist-antagonist therapy is clinically appropriate. The patient may have postoperative pain after same-day surgery, acute musculoskeletal injury, or pain in a patient with a history of opioid sensitivity or risk for opioid-related respiratory depression. A clinician (emergency physician, anesthesiologist, hospitalist, or advanced practice provider) evaluates the patient, documents pain severity, prior opioid exposure, allergies, and relevant vitals. After informed consent and medication reconciliation, nalbuphine hydrochloride is prepared and administered as an intramuscular or intravenous injection in 10 mg increments according to dosing guidelines. Nursing documents the drug lot, dose, route, time, and patient response. The patient is monitored for pain relief and adverse effects (sedation, nausea, dysphoria, respiratory status) and discharged or admitted based on clinical course and facility protocols.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier | Use when no other modifier applies and the service is billed in standard form |
11 |